Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Retinal Gene Therapy for Choroideremia (GEMINI)
NCT03507686Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2017
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of timrepigene emparvovec in choroideremia, sponsored by Biogen. Primary endpoints: Mean Best-Corrected Visual Acuity at Month 12, Mean Intraocular Pressure at Month 12 and 17 more. Started Nov 2017; status: completed.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on NCT03507686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507686.